Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 5/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28473856 | 0.83 | ALDH1A1 (0.47) | KDM4EGAAMAPTL3MBTL1 | |
| SCHEMBL29607692 | 0.83 | ALDH1A1 (0.47) | KDM4EGAAMAPTL3MBTL1 | |
| SCHEMBL13536859 | 0.82 | ALDH1A1 (0.41) | KDM4EGAAMAPTL3MBTL1 | |
| SCHEMBL10354594 | 0.81 | CARM1 (0.51) | PRMT1CARM1CHRNB2CHRNA4 | |
| SCHEMBL13425381 | 0.79 | FAAH (0.40) | KDM4EGAAMAPTL3MBTL1 | |
| SCHEMBL5044623 | 0.78 | PDE1B (0.43) | F10 | |
| SCHEMBL5045220 | 0.76 | TAAR1 (0.57) | SIGMAR1CHRNB2CHRNA4KDM4EGAA | |
| SCHEMBL611713 | 0.76 | ALDH1A1 (0.47) | CHRNB2CHRNA4KDM4EGAAMAPT | |
| SCHEMBL31093399 | 0.76 | ALDH1A1 (0.47) | CHRNB2CHRNA4KDM4EGAAMAPT | |
| SCHEMBL31093396 | 0.76 | ALDH1A1 (0.47) | CHRNB2CHRNA4KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345038-B2 | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives | PFIZER, INC (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1608648-A1 | PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES | Pfizer Products Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050026922-A1 | For treating CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression; side effect reduction; for example, (7R,9aS)-trans-7-[6-(2,6-Dimethyl-piperidin-1-ylmethyl)-pyridin-2-yloxymethyl]-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine | PFIZER INC | 2005-02-03 | — | — | US | disclosed |
| WO-2004081007-A1 | PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026922-A1 | For treating CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression; side effect reduction; for example, (7R,9aS)-trans-7-[6-(2,6-Dimethyl-piperidin-1-ylmethyl)-pyridin-2-yloxymethyl]-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine | GRM7, GRIN2C, HTR7 | SIGMAR1 390/4885PRMT1 2812/4885CARM1 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.